Bradley Foster & Sargent Inc. CT Invests $534,000 in DENTSPLY SIRONA Inc. $XRAY

Bradley Foster & Sargent Inc. CT bought a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) in the third quarter, Holdings Channel.com reports. The firm bought 42,066 shares of the medical instruments supplier’s stock, valued at approximately $534,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA during the 1st quarter valued at about $26,000. Parkside Financial Bank & Trust boosted its holdings in shares of DENTSPLY SIRONA by 620.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,715 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 1,477 shares during the last quarter. True Wealth Design LLC grew its position in shares of DENTSPLY SIRONA by 273.0% in the second quarter. True Wealth Design LLC now owns 2,376 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 1,739 shares in the last quarter. Central Pacific Bank Trust Division increased its holdings in shares of DENTSPLY SIRONA by 100.0% in the third quarter. Central Pacific Bank Trust Division now owns 4,000 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Versant Capital Management Inc lifted its position in DENTSPLY SIRONA by 878.6% during the third quarter. Versant Capital Management Inc now owns 4,883 shares of the medical instruments supplier’s stock worth $62,000 after buying an additional 4,384 shares in the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $12.71 on Friday. The firm has a 50 day moving average of $12.35 and a two-hundred day moving average of $12.47. The stock has a market capitalization of $2.54 billion, a PE ratio of -2.88, a P/E/G ratio of 1.01 and a beta of 1.01. The company has a quick ratio of 0.99, a current ratio of 1.47 and a debt-to-equity ratio of 1.36. DENTSPLY SIRONA Inc. has a 52 week low of $9.85 and a 52 week high of $19.03.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The company had revenue of $961.00 million during the quarter, compared to analysts’ expectations of $926.40 million. During the same quarter last year, the business posted $0.26 earnings per share. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, research analysts predict that DENTSPLY SIRONA Inc. will post 1.84 EPS for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were given a dividend of $0.16 per share. The ex-dividend date of this dividend was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 5.0%. DENTSPLY SIRONA’s payout ratio is currently -14.48%.

Key Headlines Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Q4 sales topped estimates — reported net sales of $961M (up 6.2% y/y; beat Street sales estimates), which triggered an initial stock rally. Dentsply Sirona’s (NASDAQ:XRAY) Q4 CY2025 sales top estimates, stock soars
• Positive Sentiment: Company announced a Return-to-Growth Action Plan redirecting ~ $120M annually toward innovation, clinical education and sales — a capital reinvestment that management says is aimed at accelerating revenue growth. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Positive Sentiment: New commercial moves — updated distributor agreements (Patterson, Benco, Burkhart, A-dec) and a U.S. product entry (Surity™ female external catheter) add distribution breadth and product diversification. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Positive Sentiment: Board refresh — appointment of three experienced directors (former Morgan Stanley, IDEXX CFO, and Patterson CEO) could strengthen governance and execution of the turnaround. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Neutral Sentiment: Adjusted EPS was $0.27 (in line with management’s adjusted figure but missed the consensus by $0.01); revenue growth is positive year-over-year — investors will watch margin recovery under the turnaround plan. Dentsply (XRAY) Reports Q4 Earnings: What Key Metrics Have to Say
• Negative Sentiment: GAAP net loss of $146M (diluted loss $0.74) was driven by ~$144M of goodwill and intangible impairments — the large non‑cash charge clouds near-term reported profitability. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Negative Sentiment: FY-2026 guidance shows adjusted EPS $1.40–1.50 (near consensus) but revenue guidance $3.5–3.6B is below the ~$3.7B consensus; management also eliminated the dividend to fund debt reduction and buybacks — a capital-allocation shift that may concern income investors. Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook
• Negative Sentiment: Halper Sadeh LLC announced an investigation into whether officers/directors breached fiduciary duties — introduces legal/management uncertainty. HALPER SADEH LLC ENCOURAGES DENTSPLY SIRONA INC. SHAREHOLDERS TO CONTACT THE FIRM

Wall Street Analysts Forecast Growth

XRAY has been the subject of several analyst reports. Stifel Nicolaus set a $13.00 target price on DENTSPLY SIRONA in a report on Thursday, November 6th. Wells Fargo & Company dropped their price objective on shares of DENTSPLY SIRONA from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Barclays began coverage on shares of DENTSPLY SIRONA in a research report on Monday, December 8th. They set an “underweight” rating and a $12.00 price objective for the company. UBS Group decreased their target price on shares of DENTSPLY SIRONA from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. Finally, Zacks Research downgraded shares of DENTSPLY SIRONA from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. Three investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $14.46.

Insider Buying and Selling at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.50% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.